Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15636943 | 0.86 | KDM4E (0.34) | KDM4EALDH1A1ALOX15HSD17B10MEN1 | |
| SCHEMBL4037522 | 0.81 | HTT (0.38) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL17050115 | 0.75 | KDM4E (0.49) | KDM4EALDH1A1ALOX15HSD17B10MEN1 | |
| SCHEMBL4038616 | 0.75 | XDH (0.38) | ALDH1A1 | |
| SCHEMBL15635981 | 0.74 | MAPK1 (0.40) | KDM4EALDH1A1KMT2A | |
| SCHEMBL31133215 | 0.74 | HTR2C (0.39) | KDM4EALDH1A1ALOX15HSD17B10MEN1 | |
| SCHEMBL31132873 | 0.74 | HTR2C (0.39) | KDM4EALDH1A1ALOX15HSD17B10MEN1 | |
| SCHEMBL4046607 | 0.74 | HCAR3 (0.37) | — | |
| SCHEMBL4037048 | 0.73 | CSNK2A1 (0.33) | — | |
| SCHEMBL17050929 | 0.72 | GPR119 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268443-B1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-6972297-B2 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-12-06 | — | — | US | disclosed |
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-19 | — | — | US | disclosed |
| EP-1268443-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SmithKline Beecham p.l.c. (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074788-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | MSH6, MSH2, PMS2 | KDM4E 1084/4885ALDH1A1 1967/4885ALOX15 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.